BioSpace News Archive

Drug Development

Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy

Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink ™ Therapy.

March 14, 2022
·
4 min read
Biotech Bay

Potrero Medical CEO Joe Urban to Present at 2022 LSI Emerging MedTech Summit

Potrero Medical, announced today that Joe Urban , Potrero’s Chief Executive Officer, has been invited to present at the 2022 Life Science Intelligence (LSI) Emerging MedTech Summit on Thursday, March 17.

March 14, 2022
·
1 min read
Genetown

Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference

Biogen Inc. (Nasdaq: BIIB) today announced new data and updates from its SPINRAZA® (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RESPOND and NURTURE studies.

March 14, 2022
·
11 min read
Business

Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update

Gracell Biotechnologies Inc. today reported fourth quarter and full year unaudited financial results for the period ended December 31, 2021, and provided corporate updates.

March 14, 2022
·
13 min read
Business

NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

NexImmune, Inc. today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health.

March 14, 2022
·
4 min read
Business

Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors

Crinetics Pharmaceuticals, Inc. today announced the appointment of Caren Deardorf to the company’s board of directors.

March 14, 2022
·
5 min read
Business

Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2021.

March 14, 2022
·
12 min read
Drug Development

BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

BridgeBio Pharma, Inc. today announced positive data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i).

March 14, 2022
·
9 min read
Drug Development

Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL™ Study of EB-101 in RDEBTopline data from VIITAL™ expected in the third quarter of 2022

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that target enrollment has been achieved in its pivotal Phase 3 VIITAL™ study.

March 14, 2022
·
6 min read
Pharm Country

Dante Labs unveils Dante Genomics, the Company’s B2B global online marketplace delivering genomic solutions for medical professionals, researchers and pharma

Dante Labs today announced the launch of Dante Genomics, an online marketplace portal specifically dedicated to healthcare providers, clinics, researchers and governments which will offer advanced genomic services for research and clinical applications.

March 14, 2022
·
2 min read